# PRODUCT INFORMATION



## GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) (trifluoroacetate salt)

Item No. 24887

Synonyms: Glucagon-like Peptide-1 (7-37) (human, bovine,

guinea pig, mouse, rat)

 $C_{151}H_{228}N_{40}O_{47} \bullet XCF_3COOH$ 

MF: FW: 3,355.7

**Purity:** ≥95%

Supplied as: A lyophilized powder

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### **Laboratory Procedures**

Glucagon-like peptide 1 (GLP-1) (7-37) (human, bovine, guinea pig, mouse, rat) (trifluoroacetate salt) is supplied as a lyophilized powder. A stock solution may be made by dissolving the GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) (trifluoroacetate salt) in water. The solubility of GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) (trifluoroacetate salt) in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

#### Description

GLP-1 (7-37) is an endogenous incretin hormone and truncated form of GLP-1 (1-37) (Item No. 24460) that is produced via cleavage of preproglucagon in the pancreas and intestine.  $^{1}$  It binds to  $\beta$ TC-1 and RIN 1027-B2 cells ( $K_{ds} = 3.3$  and 3.5 nM, respectively) and enhances insulin secretion in  $\beta$ TC-1 cells in a concentration- and glucose-dependent manner.<sup>2</sup> Ex vivo, GLP-1 (7-37) stimulates insulin release from perfused rat pancreas. GLP-1 (7-37) increases plasma insulin concentrations by greater than 50% as compared to vehicle control in response to hyperglycemia in rats when administered at a dose of 15 pmol/min/kg for five days.<sup>3</sup>

#### References

- 1. Mojsov, S., Weir, G.C., and Habener, J.F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79(2), 616-619 (1987).
- 2. Fehmann, H.C. and Habener, J.F. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett. 279(2), 335-340 (1991).
- 3. Hargrove, D.M., Nardone, N.A., Persson, L.M., et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44(9), 1231-1237 (1995).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/06/2022

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-

Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-

Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH

XCF<sub>3</sub>COOH

#### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA **PHONE:** [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM